Stent treatment of thoracic aortic pathologies, including aneurysms, pseudo-aneurysms, dissections, intramural hematomas, penetrating ulcers and ruptures of the isthmus, seems to provide a likely benefit compared to surgery in terms of surgical mortality and severe morbidity. However, the data concerning the long-term fate of these stents are insufficient. For this reason, the French National Health Authority (HAS) requests a 5-year follow-up in relation to the renewal of insurance reimbursement for these stent-grafts. Therefore, this long-term observational study has been set up.
Study outline: French observational, prospective, multi-center, non-randomized, single arm and open-label study. Study device: RELAY PLUS and RELAY NBS PLUS thoracic aortic stent or future range extension models, excluding custom-made devices. A total of 160 patients will be included in France consecutively from all participating centers and among users of the studied stent-graft (all of the centers) or any new center during the inclusion period. The patient will be considered as included in the study when the RELAY PLUS or RELAY NBS PLUS stent-graft is introduced via the surgical or percutaneous approach and provided that the patient meets all of the study eligibility criteria. The primary endpoint of this study is the 5-year mortality rate (all causes). The objective will be to assess the interest of the technique in terms of the long-term efficacy and safety of the use of the RELAY PLUS or RELAY NBS PLUS stent-graft (i.e. at 5 years) on a cohort of patients representative of the population treated under actual conditions of use. The implantation of the RELAY PLUS or RELAY NBS PLUS thoracic aortic stent-graft must be carried out in accordance with recommendations issued by the Haute Autorité de Santé (HAS) including: * Carrying out the implantation in centers with expertise in both endovascular and surgical treatments, and with an adequate technical platform. * The implementation of a multidisciplinary discussion, in particular on the risk of surgical conversion and the possible use of cardiopulmonary bypass (CPB). * Verification of the presence of a proximal neck of at least 2 cm in length, allowing for the stent to be placed. * The need to educate patients about the advantages and disadvantages of the repair techniques available, such as open surgery and endo-aortic stent (EAS). * Annual monitoring by CT-scan with contrast, or MRI + x-ray. As this study is observational, no specific examination or procedure outside the framework of the current practice of each center is required. A summary report will be submitted annually to the Haute Autorité de Santé (HAS). The final report was submitted on 31July2024
Study Type
OBSERVATIONAL
Enrollment
170
Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel - HCL
Bron, France
CHU de Créteil - Hôpital Henri Mondor
Créteil, France
Hôpital Edouard Herriot - HCL
Lyon, France
Hôpital Européen Georges Pompidou
Paris, France
CHU de Bordeaux - Hôpital Haut Lévêque
Pessac, France
CHU Rennes - Hôpital Pontchaillou
Rennes, France
CHU de Rouen - Hôpital Charles Nicolle
Rouen, France
CHU Saint Etienne - Hôpital Nord
Saint-Etienne, France
Hôpitaux Universitaires de Strasbourg - NHC
Strasbourg, France
Clinique du Tonkin
Villeurbanne, France
Long-term all-cause mortality
Time frame: Any death occurring between the surgery when the stent-graft is introduced through the arterial access and the last follow-up at 5 years
Rate of exclusion of the aneurysm, penetrating aortic ulcer, false channel or rupture site, with no endoleak of any type
Time frame: Postoperatively or in the month following the intervention, 1 year, 2 years, 3 years, 4 years, 5 years
Rate of neurological complications
Time frame: Postoperatively or in the month following the intervention, 1 year, 2 years, 3 years, 4 years, 5 years
Rate of cardiac, renal and pulmonary complications
Time frame: Postoperatively or in the month following the intervention, 1 year, 2 years, 3 years, 4 years, 5 years
Rate of device-related complications
Time frame: Postoperatively or in the month following the intervention, 1 year, 2 years, 3 years, 4 years, 5 years
Surgical conversion rate
Time frame: Postoperatively or in the month following the intervention, 1 year, 2 years, 3 years, 4 years, 5 years
Secondary procedure rate
Time frame: Postoperatively, 1 year, 2 years, 3 years, 4 years, 5 years
Pathology-related mortality rate
Time frame: Postoperatively or in the month following the intervention, 1 year, 2 years, 3 years, 4 years, 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.